Pharmaceutical Data & Analytics
Pharma Intelligence offers a range of pharmaceutical research
and analytics tools to help you identify and evaluate strategic opportunities within the global pharmaceutical market. With pharmaceutical data
and analysis from the foremost industry leading experts in the pharma market, you will have access to competitor and market access intelligence, as well as the ability to benchmark and monitor with alerts. Formulate trial strategy and protocol design using current pharmaceutical industry trends and data analysis from tools like Datamonitor Healthcare, Trialtrove, Sitetrove and Biomedtracker. See a full list of pharmaceutical data
and analytics tools from Informa Pharma Intelligence below.
Sitetrove - Clinical Trial Management
With over 350,000 experienced clinical trial investigators and clinical trial sites in over 170 countries, Sitetrove provides you with access to a wealth of data and analytical tools to help ensure your clinical trial is a success. Find out more about Sitetrove’s, Clinical Trial Management solution.
Trialtrove – Clinical Trial Competitor Intelligence
Track your competitors' clinical trial R&D activity with Trialtrove. Trialtrove is the world’s most comprehensive real-time source of pharmaceutical clinical trials intelligence, supported by experienced industry analysts. Find out more about Trialtrove’s, Clinical Trial Competitor Intelligence.
Pharmaprojects - Clinical drug development database
Pharmaprojects is the go-to resource for comprehensive coverage of preclinical, clinical pipeline coverage and drug life-cycle management tracking. Find out more about Pharmaprojects, Pipeline Drug Development Database and how it can help you.
Datamonitor Healthcare – Pharmaceutical market research & forecasting
Datamonitor Healthcare, provides accurate and objective drug sales forecast data and segmented patient based disease forecasts and analysis which is continually updated in reaction to key changes in the pharmaceutical market. Find out more about how Datamonitor Healthcare can keep you abreast of Pharmaceutical Market Trends.
Biomedtracker – Drug development approval process
With Biomedtracker you see the Drug Development Market through the analysts' eyes with an inside view to likelihood of drug approval
by regulatory bodies. We track impactful future catalysts, analyze these commercial, clinical and regulatory activities and their impact on the pharma market and drug development landscape. See how Biomedtracker can aid your decision making with insights on the Drug Development Approval Process.
Medtrack – Track Biotech and Healthcare Companies
Medtrack tracks the companies and organizations that span the drug development continuum, from contract manufacturing, to pharmaceutical R&D, to technologies, to chemical manufacturers. Medtrack monitors products, deals, financials, patents, company contacts for these Healthcare Companies.
Strategic Transactions – Analyze and Track Healthcare Deals
With coverage spanning pharmaceutical, biotech, medtech, and in vitro diagnostics companies, Strategic Transactions helps you with analyzing and tracking healthcare mergers
, acquisitions and deals globally. Structure your pharmaceutical strategies on proven data from over 25 years of global M&A, financing, and alliance activity data.
Meddevicetracker - Analysis of device markets, companies and products
Anticipate upcoming filings, research clinical trial dates and data, and access device market size information and expert forecasts, all in one place. The flexible interface lets you access real-time analysis of medical device markets
, companies and products.
Pharmapremia – Comprehensive pharmaceutical data in a web based application
With Pharmapremia you can effectively manage your portfolio risk by accessing comprehensive data sets (Pharma Big Data) and pharmaceutical statistics
to help determine Probability of Overall Success (POS), Likelihood of Approval (LOA) and Phase and Overall Duration.
Data and analysis related articles:
Orphan drug pricing and the next five years
Scrip Asks… What Will Happen In Orphan Drug Pricing In The Next Five Years? ...click to read more
How to Mitigate the Risk of Selecting a Non-Enrolling Site for your Clinical Trial -
Other than skin cancer, prostate cancer is the most common cancer in American men with about one in seven receiving a prostate cancer diagnosis during his lifetime...
IL-6: Vying for a Sliver of the Rheumatoid Arthritis Pie -
TNF antagonists have played a major role in rheumatoid arthritis (RA) prescribing trends, even helping to make adalimumab (Humira) and etanercept (Enbrel) rank among the top selling products. Despite their success, a number of patients are intolerant or have an inadequate or inappropriate response (IR) to these products... click to read more
Pharma's Orphan Drug Activity Infographic -
More than two-fifths of new drugs approved in the US last year were orphan drugs, and there are more than 4,500 drugs in active development for rare diseases... click to read more
Market access article pack value frameworks -
Payers are tightening their grip on the rising cost of specialty drugs, and are increasingly using value frameworks to tie drug price to value. For pharma, value frameworks can be just as useful in assessing the value of therapies and getting a clear view of the relative value of your drug against the competition... click to read more
Medtech weekly round up -
Discover the top medtech stories from recent weeks...click to read more
2016 Clinical trials roundup: Steady Course or changing tides?
Here we’ll provide a high-level overview of trial activity, focused on the six major therapeutic areas (TAs) of autoimmune/inflammation, cardiovascular, CNS, infectious disease, metabolic/endocrinology, and oncology, with metrics by TA, trial phase, and disease... click to read more
Shortlist for care awards -
We are delighted to announce the finalists for the 2017 Clinical and Research Excellence Awards... click to read more
NSCLC Momentum Goes To Merck And Roche, Bodes Well For Combinations -
New cancer immunotherapies are doing well in lung cancer, with Merck's Keytruda picking up share in the first-line setting and Roche's Tecentriq in second-line. Bristol-Myers Squibb is banking on combo therapy to restore its momentum...click to read more
Statins forever: Is anything set to topple this class’s mighty reign? -
With the launch of Regeneron/Sanofi’s first-in-class PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor, Praluent, in July 2015 and the following launch of Amgen’s PCSK9 inhibitor, Repatha, shortly after, the treatment of dyslipidaemia has once again been thrust into the limelight, with efficacy and cost of novel treatment at the forefront of discussion ...